4Q Revenues: $10.1 billion (+1%)
4Q Earnings: $1.5 billion (+62%)
FY Revenues: $41.5 billion (+9%)
FY Earnings: $8.2 billion (+25%)
Comments: Pharmaceutical sales were $6.4 billion in the quarter (+5%) and $26.3 billion for the year (+10%), driven by growth in oncology, the cardiovascular portfolio and $2.9 billion of contributions from recently launched products including Aclasta/Reclast, Tekturna/Rasilez, Exforge, Exjade, Lucentis, Exelon Patch, Tasigna and Xolair. For the year, Gleevec/Glivec sales were $3.7 billion (+15% lc). Zometa sales were $1.4 billion, and Femara and Sandostatin sales were each $1.1 billion. Cardiovascular product sales were $6.7 billion (+10% lc) with new medicines Exforge ($406 million) and Tekturna/Rasilez ($144 million) representing half of that growth. Diovan sales were $5.7 billion (+10% lc). Vaccines and Diagnostics sales for the year were $1.8 billion (+21%). Sandoz sales were $7.6 billion (+5%). Revenues for the quarter and FY were up 8% and 5% in local currencies, respectively.
Magazine
